Pancreatic Cancer Patients in the Phase 2 OCLURANDOM Trial See a Twelve Month Progression-Free Survival of 80 Percent
Medscape Medical News reports that results have been received from the OCCLURANDOM Phase 2 trial which is the first randomized trial investigating the antitumor effect of the peptide receptor radionuclide…